

Paul J Hauptman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10641707/publications.pdf>

Version: 2024-02-01

131
papers

6,218
citations

94433

37
h-index

66911

78
g-index

133
all docs

133
docs citations

133
times ranked

6182
citing authors

#	ARTICLE	IF	CITATIONS
1	Decision Making in Advanced Heart Failure. <i>Circulation</i> , 2012, 125, 1928-1952.	1.6	678
2	Effect of Local Medical Opinion Leaders on Quality of Care for Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 1358.	7.4	432
3	Knowledge and Practices of Generalist and Specialist Physicians Regarding Drug Therapy for Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 1994, 331, 1136-1142.	27.0	387
4	Parasympathetic Nervous System and Heart Failure. <i>Circulation</i> , 2008, 118, 863-871.	1.6	377
5	Consensus statement: palliative and supportive care in advanced heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, 200-209.	1.7	321
6	Vagus Nerve Stimulation for the Treatment of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 149-158.	2.8	283
7	Digitalis. <i>Circulation</i> , 1999, 99, 1265-1270.	1.6	259
8	Variation in the Use of Cardiac Procedures after Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 1995, 333, 573-578.	27.0	210
9	Current treatment practice and outcomes. Report of the hyponatremia registry. <i>Kidney International</i> , 2015, 88, 167-177.	5.2	149
10	Rationale and study design of the INcrease Of Vagal TonE in Heart Failure study: INOVATE-HF. <i>American Heart Journal</i> , 2012, 163, 954-962.e1.	2.7	130
11	Clinical Course of Patients With Hyponatremia and Decompensated Systolic Heart Failure and the Effect of Vasopressin Receptor Antagonism With Tolvaptan. <i>Journal of Cardiac Failure</i> , 2013, 19, 390-397.	1.7	130
12	Integrating Palliative Care Into Heart Failure Care. <i>Archives of Internal Medicine</i> , 2005, 165, 374.	3.8	129
13	Anxiety disorders increase risk for incident myocardial infarction in depressed and nondepressed Veterans Administration patients. <i>American Heart Journal</i> , 2010, 159, 772-779.	2.7	128
14	Procurement and Allocation of Solid Organs for Transplantation. <i>New England Journal of Medicine</i> , 1997, 336, 422-431.	27.0	122
15	DIALKYLAMINOBENZONITRILES AS FLUORESCENCE POLARITY PROBES FOR AQUEOUS SOLUTIONS OF CYCLODEXTRINS. <i>Photochemistry and Photobiology</i> , 1984, 39, 597-601.	2.5	112
16	Identifying Patients Hospitalized With Heart Failure at Risk for Unfavorable Future Quality of Life. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 389-398.	2.2	111
17	Physician Attitudes Toward End-Stage Heart Failure: A National Survey. <i>American Journal of Medicine</i> , 2008, 121, 127-135.	1.5	93
18	Implantable Cardiac Device Procedures in Older Patients. <i>Archives of Internal Medicine</i> , 2010, 170, 631-7.	3.8	90

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Risk Assessment Among Potential Kidney Transplant Candidates: Approaches and Controversies. <i>American Journal of Kidney Diseases</i> , 2010, 55, 152-167.	1.9	87
20	A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Tolvaptan Monotherapy Compared to Furosemide and the Combination of Tolvaptan and Furosemide in Patients With Heart Failure and Systolic Dysfunction. <i>Journal of Cardiac Failure</i> , 2011, 17, 973-981.	1.7	87
21	Patient Perceptions, Physician Communication, and the Implantable Cardioverter-Defibrillator. <i>JAMA Internal Medicine</i> , 2013, 173, 571.	5.1	85
22	The Heart Failure Clinic: A Consensus Statement of the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2008, 14, 801-815.	1.7	80
23	Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2010, 12, 367-374.	7.1	78
24	Chronic inotropic therapy in end-stage heart failure. <i>American Heart Journal</i> , 2006, 152, 1096.e1-1096.e8.	2.7	77
25	Increased Risk of Myocardial Infarction in Depressed Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 1729-1734.	8.6	73
26	Association of Anxiety Disorders and Depression With Incident Heart Failure. <i>Psychosomatic Medicine</i> , 2014, 76, 128-136.	2.0	61
27	Digoxin Use and Digoxin Toxicity in the Post-DIG Trial Era. <i>Journal of Cardiac Failure</i> , 2006, 12, 343-346.	1.7	60
28	Use of Nesiritide Before and After Publications Suggesting Drug-Related Risks in Patients With Acute Decompensated Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1877.	7.4	59
29	Antidepressant Drug Compliance: Reduced Risk of MI and Mortality in Depressed Patients. <i>American Journal of Medicine</i> , 2011, 124, 318-324.	1.5	59
30	Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. <i>British Journal of Psychiatry</i> , 2012, 200, 137-142.	2.8	58
31	Hospice Care for Heart Failure Patients. <i>Journal of Pain and Symptom Management</i> , 2005, 29, 525-528.	1.2	52
32	SAFETY, TOLERABILITY AND EFFICACY OF CYCLOSPORINE MICROEMULSION IN HEART TRANSPLANT RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND COMPARISON WITH THE OIL BASED FORMULATION OF CYCLOSPORINE - RESULTS AT SIX MONTHS AFTER TRANSPLANTATION ^{1,2} . <i>Transplantation</i> , 1999, 68, 663-671.	1.0	48
33	Rationale and Design of CASPER: Compliance and Quality of Life Study Comparing Once-Daily Carvedilol CR and Twice-Daily Carvedilol IR in Patients with Heart Failure. <i>American Journal of Cardiology</i> , 2006, 98, 60-66.	1.6	47
34	Cardiac Evaluation before Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1115-1124.	4.5	44
35	Characteristics of Patients Hospitalized With Acute Decompensated Heart Failure Who Are Referred for Hospice Care. <i>Archives of Internal Medicine</i> , 2007, 167, 1990.	3.8	41
36	Medication adherence in heart failure. <i>Heart Failure Reviews</i> , 2008, 13, 99-106.	3.9	40

#	ARTICLE	IF	CITATIONS
37	SAFETY, TOLERABILITY, AND EFFICACY OF CYCLOSPORINE MICROEMULSION IN HEART TRANSPLANT RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND COMPARISON WITH THE OIL-BASED FORMULATION OF CYCLOSPORINE???.RESULTS AT 24 MONTHS AFTER TRANSPLANTATION1. <i>Transplantation</i> , 2001, 71, 70-78.	1.0	39
38	Understanding Individual and Small Area Variation in the Underuse of Coronary Angiography Following Acute Myocardial Infarction. <i>Medical Care</i> , 2002, 40, 614-626.	2.4	38
39	Adherence With Once Daily Versus Twice Daily Carvedilol in Patients With Heart Failure: The Compliance and Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients With Heart Failure (CASPER) Trial. <i>Journal of Cardiac Failure</i> , 2009, 15, 385-393.	1.7	37
40	Variability in the clinical status of patients with advanced heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, 397-402.	1.7	36
41	Pharmacologic modulation of parasympathetic activity in heart failure. <i>Heart Failure Reviews</i> , 2011, 16, 179-193.	3.9	35
42	Heart Failure Is a Major Contributor to Hospital Readmission Penalties. <i>Journal of Cardiac Failure</i> , 2015, 21, 134-137.	1.7	35
43	Resource utilization in patients hospitalized with heart failure: Insights from a contemporary national hospital database. <i>American Heart Journal</i> , 2008, 155, 978-985.e1.	2.7	34
44	Digoxin Toxicity and Use of Digoxin Immune Fab. <i>JACC: Heart Failure</i> , 2016, 4, 357-364.	4.1	33
45	Current Management of Hyponatremia in Acute Heart Failure: A Report From the Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry). <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	33
46	Effectiveness of percutaneous coronary intervention in cardiac allograft vasculopathy. <i>American Journal of Cardiology</i> , 2004, 93, 90-92.	1.6	32
47	It Is Time To Stop Ignoring Malignancy In Heart Transplantation: A Call To Arms. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1111-1113.	0.6	32
48	Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 328-333.	1.0	30
49	Underutilization of β -Blockers in Patients Undergoing Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Procedures. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 204-211.	2.2	27
50	Variability in Retail Pricing of Generic Drugs for Heart Failure. <i>JAMA Internal Medicine</i> , 2017, 177, 126.	5.1	27
51	Implantable Defibrillators and Cardiac Resynchronization Therapy in Heart Transplant Recipients: Results of a National Survey. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 847-850.	0.6	22
52	Health-related quality of life measurement in heart failure: Challenges for the new millennium. <i>Journal of Cardiac Failure</i> , 2001, 7, 194-201.	1.7	21
53	Palliative Care for Patients With End-Stage Cardiovascular Disease and Devices. <i>JAMA Internal Medicine</i> , 2016, 176, 1017.	5.1	21
54	Angiography of potential cardiac donors. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1252-1258.	2.8	20

#	ARTICLE	IF	CITATIONS
55	Mode of Death From Congestive Heart Failure: Implications for Clinical Management. <i>The American Journal of Geriatric Cardiology</i> , 2004, 13, 299-304.	0.6	19
56	Errata in Medical Publications. <i>American Journal of Medicine</i> , 2014, 127, 779-785.e1.	1.5	19
57	Pitfalls in assessing the quality of care for patients with cardiovascular disease. <i>American Journal of Medicine</i> , 2001, 111, 297-303.	1.5	18
58	Bundling Informed Consent and Advance Care Planning in Chronic Cardiovascular Disease. <i>JAMA Internal Medicine</i> , 2015, 175, 5.	5.1	18
59	Reference Laboratory Values for Digoxin Following Publication of Digitalis Investigation Group (DIG) Trial Data. <i>JAMA Internal Medicine</i> , 2013, 173, 1552.	5.1	17
60	Heart Failure, Shared Decision-making, and Social Determinants of Health. <i>JAMA Cardiology</i> , 2019, 4, 609.	6.1	16
61	Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2021, 27, 2-19.	1.7	16
62	Progression of coronary artery disease in non-ischemic dilated cardiomyopathy. <i>Coronary Artery Disease</i> , 2004, 15, 291-297.	0.7	15
63	Quality of life in advanced heart failure: Role of mitral regurgitation. <i>American Heart Journal</i> , 2006, 151, 213-218.	2.7	15
64	Palliation in heart failure: When less and more are more. <i>American Journal of Hospice and Palliative Medicine</i> , 2006, 23, 150-152.	1.4	14
65	Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. <i>Pharmacoeconomics</i> , 2018, 36, 1463-1473.	3.3	14
66	Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. <i>Clinical Cardiology</i> , 2002, 25, 247-249.	1.8	13
67	Short-term mortality and cost associated with cardiac device implantation in patients hospitalized with heart failure. <i>American Heart Journal</i> , 2008, 156, 322-328.	2.7	12
68	Device therapy in patients with heart failure and advanced age: Too much too late?. <i>International Journal of Cardiology</i> , 2012, 155, 52-55.	1.7	12
69	The vagus nerve and autonomic imbalance in heart failure: past, present, and future. <i>Heart Failure Reviews</i> , 2011, 16, 97-99.	3.9	11
70	Clinical Trial Design in Contemporary Device Studies in Heart Failure: Is There a Gold Standard?. <i>Journal of Cardiac Failure</i> , 2014, 20, 223-228.	1.7	10
71	Incremental Utility of Iodine-123 Meta-Iodobenzylguanidine Imaging Beyond Established Heart Failure Risk Models. <i>Journal of Cardiac Failure</i> , 2014, 20, 577-583.	1.7	10
72	Micronutrient Deficiencies in Patients With Heart Failure: Relationships With Body Mass Index and Age. <i>Journal of Cardiac Failure</i> , 2015, 21, 968-972.	1.7	9

#	ARTICLE	IF	CITATIONS
73	Advancing the Research Mission in a Time of Mergers and Acquisitions. JAMA - Journal of the American Medical Association, 2017, 318, 1321.	7.4	9
74	A Survey of Unregulated Direct-to-Consumer Treatment Centers Providing Stem Cells for Patients With Heart Failure. JAMA Internal Medicine, 2017, 177, 1387.	5.1	9
75	Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 756-767.	3.0	9
76	Reducing Bias in Academic Search Committees. JAMA - Journal of the American Medical Association, 2016, 316, 2595.	7.4	8
77	Deactivation of Ventricular Assist Devices: Perspectives and Experiences of Adult Cardiovascular Providers. Journal of Cardiac Failure, 2017, 23, 485-486.	1.7	8
78	Left Ventricular Assist Device. New England Journal of Medicine, 2002, 346, 1023-1025.	27.0	6
79	Clinical challenge of hyponatremia in heart failure. Journal of Hospital Medicine, 2012, 7, S6-10.	1.4	6
80	Evaluation and Management of Potential Heart Donors for Transplantation. Cardiology in Review, 1998, 6, 100-106.	1.4	5
81	Nutrition in Heart Failure: More Than Drugs and Devices. Journal of Cardiac Failure, 2015, 21, 943-944.	1.7	5
82	Autonomic Modulation in Heart Failure: Ready for Prime Time?. Current Cardiology Reports, 2015, 17, 103.	2.9	5
83	Unmet Needs and Prioritization in Heart Failure. Journal of Cardiac Failure, 2016, 22, 587-588.	1.7	5
84	Disease Modification in Acute Decompensated Heart Failure. New England Journal of Medicine, 2017, 376, 1987-1988.	27.0	4
85	Vasopressin antagonism for decompensated right-sided heart failure. International Journal of Cardiology, 2019, 274, 245-247.	1.7	4
86	Does It Matter Why and How Patients With Heart Failure Die?. Circulation: Heart Failure, 2008, 1, 89-90.	3.9	3
87	β ₂ -Adrenergic receptor blockers and heart failure risk after myocardial infarction: A critical review. Current Heart Failure Reports, 2009, 6, 220-228.	3.3	3
88	Addressing disparities in heart failure care without borders. European Journal of Heart Failure, 2015, 17, 753-754.	7.1	3
89	Patient, Physician, and Practice Characteristics Associated with Cardiovascular Disease Preventive Care for Women. Journal of Women's Health, 2017, 26, 491-499.	3.3	3
90	Measurement of end points in heart failure trials: jousting at windmills?. Mount Sinai Journal of Medicine, 2004, 71, 298-304.	1.9	3

#	ARTICLE	IF	CITATIONS
91	The Business Concept of Leader Pricing as Applied to Heart Failure Disease Management. <i>Disease Management: DM</i> , 2004, 7, 226-234.	1.0	2
92	Inotropic Therapy. <i>Medical Clinics of North America</i> , 2012, 96, 943-954.	2.5	2
93	It's Not Just Nomenclature, It's a Patient With Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 611.	1.7	2
94	Impact or Impact Factor?. <i>Journal of Cardiac Failure</i> , 2016, 22, 751-752.	1.7	2
95	Variations on a Precision Medicine Theme. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	2
96	Heart Failure Is Not Going Anywhere: Good News, Bad News. <i>Journal of Cardiac Failure</i> , 2017, 23, 271.	1.7	2
97	Reconfiguring the Hospital-to-Home Transition Into an Active Treatment Period for Patients With Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 467.	6.1	2
98	Global Health and Heart Failure. <i>Journal of Cardiac Failure</i> , 2018, 24, 1-2.	1.7	2
99	Chest Pain, Atherosclerotic Cardiovascular Disease Risk, and Cardiology Referral in Primary Care. <i>Journal of Primary Care and Community Health</i> , 2018, 9, 215013271877325.	2.1	2
100	Social Media and the Journal: Entering a New Era. <i>Journal of Cardiac Failure</i> , 2018, 24, 415-416.	1.7	2
101	Progression of Coronary Artery Disease in Non-Ischemic Dilated Cardiomyopathy: An Under-Estimated Phenomenon?. <i>Journal of Cardiac Failure</i> , 2003, 9, S99.	1.7	1
102	Anything does not go: Defining and refining interventions designed to improve quality in cardiovascular diseases. <i>American Journal of Medicine</i> , 2004, 117, 433-435.	1.5	1
103	Implantation of cardiac defibrillators for primary prevention: a pendulum too far?. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1047-1050.	1.5	1
104	Unmeasured Confounders and Predictive Models: What's Your C-Statistic?. <i>Journal of Cardiac Failure</i> , 2015, 21, 857-858.	1.7	1
105	Arrhythmias in a long-term adult survivor with uncorrected tetralogy of Fallot: Case report and review of the literature. <i>Journal of Electrocardiology</i> , 2015, 48, 734-738.	0.9	1
106	Crossing the Generational Divide. <i>Journal of Cardiac Failure</i> , 2015, 21, 699.	1.7	1
107	The Readmissions Obsession and Magical Numbers. <i>Journal of Cardiac Failure</i> , 2015, 21, 365-366.	1.7	1
108	New Editors, Same Dedication to Excellence. <i>Journal of Cardiac Failure</i> , 2015, 21, 1.	1.7	1

#	ARTICLE	IF	CITATIONS
109	In Heart Failure, You Can Embrace Your Inner Provocateur. <i>Journal of Cardiac Failure</i> , 2016, 22, 657-658.	1.7	1
110	Vulnerability in Heart Failure. <i>Journal of Cardiac Failure</i> , 2018, 24, 485-486.	1.7	1
111	Drug discount cards in an era of higher prescription drug prices: A retrospective population-based study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 804-808.e1.	1.5	1
112	Implantable Cardioverter/Defibrillators in the Primary Prevention of Sudden Death: We Know What to Do but Are We Doing It?. <i>JAMA - Journal of the American Medical Association</i> , 2012, 172, 67-8.	0.8	0
113	Extreme Reverse Remodeling in a Patient With Dilated Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2014, 7, 1063-1065.	3.9	0
114	Man and VAD: Deus Ex Machina. <i>Journal of Cardiac Failure</i> , 2015, 21, 783-784.	1.7	0
115	A Case of Possible Pacemaker Undersensing. <i>JAMA Internal Medicine</i> , 2015, 175, 1050.	5.1	0
116	Do We Have Consensus About Consensus Statements?. <i>Journal of Cardiac Failure</i> , 2015, 21, 437-438.	1.7	0
117	An April Potpourri: Mini Focus Issues, Brief Reports, Podcasts, Biomarkers, Cognition, and More. <i>Journal of Cardiac Failure</i> , 2015, 21, 261-262.	1.7	0
118	The Third and Fourth Decades. <i>Journal of Cardiac Failure</i> , 2016, 22, 321-322.	1.7	0
119	Cardio-oncology: We Have Much to Learn. <i>Journal of Cardiac Failure</i> , 2016, 22, 407-408.	1.7	0
120	We Have Skin in the Game: Not the Headline You Expected to See. <i>Journal of Cardiac Failure</i> , 2016, 22, 1-2.	1.7	0
121	Got Big Data?. <i>Journal of Cardiac Failure</i> , 2016, 22, 169-170.	1.7	0
122	Looking Back at Baltimore 1997. <i>Journal of Cardiac Failure</i> , 2017, 23, 1.	1.7	0
123	Taking Stock. <i>Journal of Cardiac Failure</i> , 2017, 23, 515-516.	1.7	0
124	The Barber, the Tell, and the Teapot. <i>Journal of Cardiac Failure</i> , 2017, 23, 717-718.	1.7	0
125	Henry and Mount Rushmore. <i>Journal of Cardiac Failure</i> , 2017, 23, 657-658.	1.7	0
126	How We are Doing: The Journal Enters Its 25 th Year. <i>Journal of Cardiac Failure</i> , 2017, 23, 833-834.	1.7	0

#	ARTICLE	IF	CITATIONS
127	Defining RTUs and RRUs for Heart Failure Care. Journal of Cardiac Failure, 2018, 24, 207-208.	1.7	0
128	Updated Genetics Guidelines: An Important Step Forward. Journal of Cardiac Failure, 2018, 24, 279-280.	1.7	0
129	The Importance of Using Correct Terms. Journal of Cardiac Failure, 2018, 24, 347-348.	1.7	0
130	How Much Validation Do We Need?. Journal of Cardiac Failure, 2019, 25, 493.	1.7	0
131	The New Kids on the Block: Don't Delay. Journal of Cardiac Failure, 2020, 26, 811-812.	1.7	0